Beckett P R, Llupiá J, Lumachi B, Roberts D J
Arzneimittelforschung. 1984;34(10A):1367-70.
Pharmacological screening tests have been done in order to provide an initial assessment of the new antacid compound almagate (aluminium-magnesium hydroxycarbonate hydrate, Al2Mg6(OH)14(CO3)2 X 4 H2O, Almax). In rats with pyloric ligatures, almagate (125-500 mg/kg) was significantly more potent than aluminium hydroxide in raising the pH and reducing the total acidity of the gastric juice produced, without affecting the volume secreted. Pepsin activity in the gastric juice was also significantly inhibited by almagate even after adjustment to the optimal enzyme pH 2, a phenomenon not demonstrable with aluminium hydroxide. Almagate in oral doses up to 3 g/kg was without effects on the central, autonomic and somatic nervous systems in mice, nor at 500 mg/kg did it influence the cardiovascular system or blood pressure responses to agonist drugs in anaesthetised cats. The results confirm almagate to be a potent antacid drug devoid of systemic pharmacological or toxicological effects.
为了对新型抗酸化合物铝碳酸镁（水合氢氧化铝镁，Al2Mg6(OH)14(CO3)2·4H2O，Almax）进行初步评估，已开展了药理学筛选试验。在幽门结扎的大鼠中，铝碳酸镁（125 - 500mg/kg）在提高胃液pH值和降低胃液总酸度方面比氢氧化铝更有效，且不影响胃液分泌量。即使将胃液pH值调至最佳酶活性pH值2后，铝碳酸镁仍能显著抑制胃液中的胃蛋白酶活性，而氢氧化铝则无此现象。口服剂量高达3g/kg的铝碳酸镁对小鼠的中枢、自主和躯体神经系统均无影响，在麻醉猫中，500mg/kg的铝碳酸镁也不影响心血管系统或对激动剂药物的血压反应。结果证实铝碳酸镁是一种有效的抗酸药物，无全身药理学或毒理学作用。
